Oncology Precision Medicine Market, Size, Share, Outlook | Forecast (2023 - 2028) | Renub Research

Oncology Precision Medicine Market, Size, Share, Outlook | Forecast (2023 – 2028) | Renub Research

April 18, 2024
0 Comments

Oncology Precision Medicine Market, Size, Global Forecast 2022-2028, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis. The report also includes an analysis of the competitors, geographic regions, and expansion into Global Oncology Precision Medicine Market.

Global Oncology Precision Medicine Market is anticipated grow at a CAGR of 10.50% between 2022 and 2028.A paradigm shift in cancer remedy has been added approximately through the dynamic and fast-growing global oncology precision medicine market. Precision medicine in oncology refers to tailoring healing procedures primarily based on patient’s genetic makeup, tumour biology, and individual characteristics. This approach is revolutionizing cancer care, presenting greater effective treatments with fewer side effects, in the long run improving patient outcomes.

Moreover, advances in genomics have revolutionized cancer care by permitting the identification of precise genetic mutations and changes propelling cancer growth, facilitating comprehensive genomic profiling. This empowers oncologists to make informed treatment choices, aligning the patient’s genetic profile with targeted healing procedures. Furthermore, precision medicines have ushered in breakthroughs in immunotherapy, leveraging the body’s immune system to combat cancer efficiently. Drugs along with checkpoint inhibitors and CAR-T cell treatment options have demonstrated remarkable achievement in treating a huge range of cancer types. Thus, the Global Oncology Precision Medicine Market is anticipated be worth US$ 123.44 Billion by 2028.

Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=oncology-precision-medicine-market-p.php

Likewise, on-going research continues to unveil novel biomarkers crucial for identifying patients who stand to benefit most from specific treatments, thereby guiding treatment decisions and enhancing response rates. Pharmaceutical firms are progressively conducting precision medicine-focused clinical trials aimed at developing and testing targeted therapies, providing patients with access to state-of-the-art treatments tailored to their individual cancer biology. Global collaboration and data sharing initiatives have played a pivotal role in expediting research and development endeavours. International partnerships involving healthcare institutions, researchers, and pharmaceutical companies have significantly broadened the knowledge base, further accelerating advancements in the field of precision medicine. 

Lung cancer is rapidly growing in the global oncology precision medicine market due to its high incidence worldwide and the urgent need for more effective treatments

Precision medicine, with its tailor-made treatments based totally on individual genetic profiles, has shown promise in enhancing lung cancer outcomes. Advances in targeted therapies, immunotherapies, and liquid biopsy diagnostics have fuelled this growth. Also, sturdy research efforts, multiplied awareness, and collaborations between pharmaceutical organizations and healthcare providers have expanded the adoption of precision medicines in lung cancer treatment, making it the quickest-developing segment in the global oncology precision medicine market.

Indication – Global Oncology Precision Medicine Market has been covered from eleven viewpoints

  1. Lung Cancer
  2. Stomach Cancer
  3. Colorectal Cancer
  4. Breast Cancer
  5. Prostate Cancer
  6. Liver Cancer
  7. Esophagus Cancer
  8. Cervical Cancer
  9. Kidney Cancer
  10. Bladder Cancer
  11. Other Cancers


Hospitals play a dominant role in the global oncology precision medicine market owing to their comprehensive patient care infrastructure.

Hospitals house specialised oncology departments, diagnostic facilities, and access to modern technologies required for precision medication. They additionally have multidisciplinary teams of professionals, consisting of oncologists, pathologists, geneticists, and pharmacists, who collaborate to tailor solutions to individual patient profiles. Moreover, hospitals are frequently the primary centers for scientific trials, permitting patients access to the today’s precision medicines. This incorporated approach and understanding make hospitals the principal hub for delivering precision medicines in the oncology market.

End-Users – Global Oncology Precision Medicine Market has been covered from four viewpoints.

  1. Hospitals
  2. Diagnostic Centers
  3. Research & Academic Institutes
  4. Others

China is substantially growing in the global oncology precision medicine market

China has made considerable investments in healthcare infrastructure and research, fostering innovation in precision medicinal drug. With a massive and numerous patient population, the nation offers an extensive pool of records for research and improvement. Moreover, the government’s aid for precision medicinal drug initiatives, and partnerships with international pharmaceutical agencies have extended its presence in the market. As a result, China has ended up as an outstanding player, providing superior precision oncology solutions and contributing to the market’s rapid growth.

Countries – Global Oncology Precision Medicine Market has been covered from twenty-one viewpoints.

  1. USA 
  2. Canada
  3. UK
  4. France
  5. Germany
  6. Italy
  7. Spain
  8. Others in Europe
  9. Japan
  10. China
  11. Korea
  12. Others in Asia
  13. Brazil
  14. Mexico
  15. Argentina
  16. Colombia
  17. Others in Latin America
  18. Saudi Arabia
  19. UAE
  20. South Africa
  21. Others in Middle East and Africa

Competitive Landscape

F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Co., and AstraZeneca are the top companies in the global oncology precision medicine market.

Company Insights

  • Overview
  • Recent Development and Initiatives
  • Sales Analysis

Analysis of the companies present in the global oncology precision medicine market

  1. F. Hoffmann-La Roche Ltd.,
  2. Novartis AG
  3. Bristol-Myers Squibb
  4. Eli Lilly and Co.,
  5. AstraZeneca

Related Reports

Cancer Immunotherapy Market size is expected to surpass around US$ 188.11 Billion by 2030

Schizophrenia Drugs Market size is projected to reach US$ 9.46 Billion by 2030

China Oncology Drugs Market size will attain a cost of US$ 42.19 Billion via 2028

About the Company: 

Renub Research is a Market Research and Information Analysis company with more than 15 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7500 syndicated reports and worked on more than 900 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.

 

Contact Us:

Renub Research        

Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)

Email: info@renub.com

LinkedIn: https://in.linkedin.com/company/renub-research

Web: www.renub.com

Add a comment

Your email address will not be published. Required fields are marked *

益生菌對人體的益處

Boo
December 25, 2024
吃不下、排不出、消化不好……都會被安利一波 “益生菌”,似乎 “益生菌” 治百病似的,而且不僅給孩子吃,大人們自己也是頻頻種草。 拉肚子了怎麽辦?——吃益生菌! 便秘了怎麽辦?——吃益生菌! 消化不良怎麽辦?——吃益生菌! 腸脹氣怎麽辦?——吃益生菌! 不愛吃飯怎麽辦?——吃益生菌! 那麽更深層次的疑問也就隨之而來:益生菌,真有這麽神嗎?日本表飛鳴益生菌,是越多越好嗎?益生菌,真的無所不能嗎?喝下去的益生菌一定會起作用嗎?河北農業大學食品科技學院高潔將爲你一一解開迷惑。 益生菌到底是什麽? 益生菌的英文名叫 Probiotic,來源于希臘語,本意是 “對生命有益”,所以顧名思義,益生菌就是對生命有益的菌,是一種通過改善人體微生物平衡從而對宿主施加有益影響的微生物,主要是細菌。 我們正常人體內,以腸道爲主,存在大量的共生菌群,超過1000萬億個,益生菌這類細菌不但不是致病菌,反而能通過改善腸道微生物的平衡,産生不可替代的生理作用。 爲了讓大家吃得放心,我國設計了一個嚴格的評審系統來給它們做身份認證,通過了的才是有名分、能作爲商品流通的益生菌。它們分別是兩岐雙岐杆菌、嬰兒雙岐杆菌、長雙岐杆菌、短雙岐杆菌、青春雙岐杆菌、德氏乳杆菌保加利亞種、嗜酸乳杆菌、幹酪乳杆菌幹酪亞種、嗜熱鏈球菌、羅伊氏乳杆菌。另外還有一組比較特殊的,叫 “可用于嬰幼兒食品的菌種”,包括嗜酸乳杆菌、動物雙歧杆菌、乳雙歧杆菌、鼠李糖乳杆菌,也屬于有名分的益生菌。 平時醫院、藥店裏所購買的一般都是益生菌制劑,益生菌制劑和益生菌不同,益生菌制劑是一種由益生菌加工而成的産品,它除了含有益生菌成分外,可能還含有食用香精、乙醇、甜菊素、麥芽糊精等等一些添加劑成分,雖然這些添加劑經國家安全認證,但不表示此類制劑可以長期服用。...
QAS Autos is a multi service company that was established in 2019 in New York. We provide the inventory, parts and service under one roof. We also provide shipping, container loading, half and full cut of vehicles.
Copyright © 2021. All rights reserved.